Literature DB >> 8343632

Contraceptives, counselling, and pregnancy in women with sickle cell disease.

R J Howard1, C Lillis, S M Tuck.   

Abstract

Sickle cell disease is listed in the manufacturers' data sheets in the United Kingdom as a contraindication to the use of most combined contraceptive pills; the result is confused advice on family planning to a group of women who are at substantial risk from both planned and unplanned pregnancy. A study in north London on the use of contraceptives by women with sickle cell disease indicates that the use of combined oral contraceptives is common. Although medical staff usually advised against pregnancy, such advice was almost always ignored. Over half of the women surveyed had some knowledge about antenatal diagnosis. Family planning advice should be an integral part of the care of women with sickle cell disease. In the absence of specific data to the contrary all methods of contraception may be considered, although with appropriate caution.

Entities:  

Keywords:  Clinic Activities; Contraception; Contraceptive Methods; Contraceptive Usage--women; Counseling; Data Aggregation; Developed Countries; Diseases; Europe; Family Planning; Genetic Counseling; Hereditary Diseases; Morbidity--women; Northern Europe; Oral Contraceptives; Organization And Administration; Program Activities; Programs; Research Methodology; United Kingdom

Mesh:

Substances:

Year:  1993        PMID: 8343632      PMCID: PMC1678269          DOI: 10.1136/bmj.306.6894.1735

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  13 in total

1.  Antenatal diagnosis. How to deliver a comprehensive service in the United Kingdom.

Authors:  M Petrou; B Modell; A Darr; J Old; E Kin; D Weatherall
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

2.  Unwanted pregnancies.

Authors:  T Smith
Journal:  BMJ       Date:  1990-05-05

3.  Counselling for prenatal diagnosis of sickle cell disease and beta thalassaemia major: a four year experience.

Authors:  E N Anionwu; N Patel; G Kanji; H Renges; M Brozović
Journal:  J Med Genet       Date:  1988-11       Impact factor: 6.318

4.  Contraception for sicklers.

Authors:  R P Perkins
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

Review 5.  Pregnancy in sickle cell disease.

Authors:  S Charache; J R Niebyl
Journal:  Clin Haematol       Date:  1985-10

6.  Stroke in a woman with sickle cell trait taking oral contraceptives.

Authors:  J G Greenwald
Journal:  Conn Med       Date:  1971-04

7.  Sickle haemoglobin and pregnancy.

Authors:  G R Serjeant
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-03

8.  Contraceptive practices and reproductive patterns in sickle cell disease.

Authors:  J H Samuels-Reid; R B Scott; W E Brown
Journal:  J Natl Med Assoc       Date:  1984-09       Impact factor: 1.798

9.  Contraceptives in sickle cell disease.

Authors:  H W Foster
Journal:  South Med J       Date:  1981-05       Impact factor: 0.954

10.  Pregnancy in sickle cell disease in the UK.

Authors:  S M Tuck; J W Studd; J M White
Journal:  Br J Obstet Gynaecol       Date:  1983-02
View more
  4 in total

1.  Sickle cell disease and contraception.

Authors:  J Guillebaud
Journal:  BMJ       Date:  1993-08-21

2.  Toward understanding family-related characteristics of young adults with sickle-cell disease or sickle-cell trait in the USA.

Authors:  Patricia E Hershberger; Agatha M Gallo; Robert Molokie; Alexis A Thompson; Marie L Suarez; Yingwei Yao; Constance M Dallas; Diana J Wilkie
Journal:  J Clin Nurs       Date:  2016-03-11       Impact factor: 3.036

Review 3.  Steroid hormones for contraception in women with sickle cell disease.

Authors:  A Manchikanti; D A Grimes; L M Lopez; K F Schulz
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

Review 4.  Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease.

Authors:  Lydia H Pecker; Deva Sharma; Alecia Nero; Michael J Paidas; Russell E Ware; Andra H James; Kim Smith-Whitley
Journal:  Br J Haematol       Date:  2021-07-07       Impact factor: 8.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.